CH
UBX

CVI Holdings’s Unity Biotechnology UBX Stock Holding History

CVI Holdings’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-74,100
Closed -$203K – 440
2022
Q4 		$203K Buy
74,100
+66,690
+900% +$194K 0.03% 270
2022
Q3 		$30K Buy
+7,410
New +$46.7K ﹤0.01% 510

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CVI Holdings's UBX Position: Q4 2022 in Review

CVI Holdings sold out of Unity Biotechnology (UBX) in Q4 2022, closing a stake of 168,415 shares — an estimated $489K sold.

CVI Holdings first reported a position in UBX in Q3 2022 and held it in 1 quarter. The position peaked at $665K in Q3 2022. 54 funds tracked by Wall St. Rank hold UBX as of Q4 2022.

  • CVI Holdings reported no remaining Unity Biotechnology position as of Q4 2022 after selling out during the quarter.
  • CVI Holdings sold 168,415 Unity Biotechnology shares in Q4 2022, an estimated $489K.
  • CVI Holdings first reported a position in Unity Biotechnology in Q3 2022 and held it in 1 quarter.
  • CVI Holdings's Unity Biotechnology position peaked at $665K in Q3 2022.
  • 54 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2022.

Based on CVI Holdings's 13F filing for Q4 2022, filed 14 Feb 2023.